Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for <i>BRAF</i>-Mutant Melanoma

Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for <i>BRAF</i>-Mutant Melanoma

No head-to-head studies exist comparing BRAF inhibitor/MEK inhibitor (BRAFi/MEKi) combination treatments for <i>BRAF-</i>mutant melanoma. A side-by-side analysis of randomized phase III trials is presented that evaluated dabrafenib/trametinib, vemurafenib/cobimetinib, and encorafenib/bin...

Full description

Bibliographic Details
Main Authors: Omid Hamid, C. Lance Cowey, Michelle Offner, Mark Faries, Richard D. Carvajal
Format: Article
Language:English
Published: MDPI AG 2019-10-01
Series:Cancers
Subjects:
binimetinib
braf inhibitor
<i>braf</i>-mutant melanoma
combination therapy
mek inhibitor
Online Access:https://www.mdpi.com/2072-6694/11/11/1642

Internet

https://www.mdpi.com/2072-6694/11/11/1642

Similar Items